NCT03993353View on ClinicalTrials.gov

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2029

Conditions

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck CarcinomaHead and Neck Cancer Stage IIIHead and Neck Cancer Stage IVHead and Neck Cancer MetastaticCancerCancer of EsophagusCancer, MetastaticCancer of Head and NeckCancer of MouthCancer of Neck

Interventions

DRUG

Pembrolizumab

200 mg intravenously every 3 weeks

DRUG

Tadalafil

10 mg by mouth daily

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors

lead

University of California, San Diego

OTHER

NCT03993353 - Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter